|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2003
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE05
|
|
gptkbp:brand
|
Iressa
|
|
gptkbp:casnumber
|
184475-35-2
|
|
gptkbp:chemical_formula
|
C22 H24 Cl FN4 O3
|
|
gptkbp:class
|
anilinoquinazoline
|
|
gptkbp:clinical_trial
|
Phase III trials
Phase II trials
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
lactation
|
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:discontinued
|
in some countries
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:dosage_form
|
250 mg once daily
|
|
gptkbp:drug_interactions
|
antacids
proton pump inhibitors
H2-receptor antagonists
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:formulation
|
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gefitinib
|
|
gptkbp:indication
|
EGFR mutation-positive NSCLC
|
|
gptkbp:interacts_with
|
gptkb:CYP2_D6
gptkb:CYP3_A4
|
|
gptkbp:is_monitored_by
|
electrolytes
pulmonary function tests
liver function tests
|
|
gptkbp:lifespan
|
approximately 48 hours
|
|
gptkbp:marketed_as
|
Iressa
|
|
gptkbp:mechanism_of_action
|
EGFR inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
adults
elderly
|
|
gptkbp:replaced_by
|
gptkb:Osimertinib
|
|
gptkbp:research_areas
|
clinical trials
oncology
pharmacology
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
vomiting
diarrhea
rash
skin reactions
electrolyte imbalances
hepatotoxicity
interstitial lung disease
eye disorders
pulmonary toxicity
|
|
gptkbp:targets
|
gptkb:EGFR
|
|
gptkbp:treatment
|
targeted therapy
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:EGFR
|
|
gptkbp:bfsLayer
|
5
|